Trial Condition(s):
Bone Neoplasms
Bonefos and the consumption of analgesics (BICAM)
Study Completed
Trial Purpose
The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.
Inclusion Criteria
- Breast cancer or prostate cancer or multiple myeloma. - Bone metastasis. - Ability to use analgesics and clodronate 1600 mg/day.
Exclusion Criteria
- Hypersensitivity to bisphosphonates. - Clodronate in previous therapy. - Concomitant use of other bisphosphonates. - Serious renal insufficiency.
Trial Summary
Enrollment Goal
149
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
Bonefos (Clodronate, BAY94-8393)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
Status
| Locations | Status | ||
|---|---|---|---|
Locations Investigative Site Many locations, Czech Republic | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Bonefos and the consumption of analgesics. Influence of clodronate on analgesics consumption among patients with bone metastasis
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Analgesics consumption after 12 months of treatment with Bonefos in patients with bone metastases and breast or prostate cancer or multiple myelomaTimeframe: 12 months
Secondary Outcome
- Decrease in pain measured by VAS (Visual Analogue Scale)Timeframe: 12 months
Additional Information
Copyright © Bayer
Powered by
